The effect of erythromycin and clarithromycin on the pharmacokinetics of intravenous digoxin in healthy volunteers

被引:19
作者
Tsutsumi, K
Kotegawa, T
Kuranari, M
Otani, Y
Morimoto, T
Matsuki, S
Nakano, S
机构
[1] Oita Med Univ, Dept Clin Pharmacol & Therapeut, Oita 8795593, Japan
[2] Oita Med Univ Hosp, Clin Pharmacol Ctr, Oita, Japan
[3] Oita Med Univ, Dept Obstet & Gynecol, Oita 8795593, Japan
关键词
D O I
10.1177/009127002401382641
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Several case reports have suggested an interaction between digoxin and macrolide antibiotics. The authors investigated the effect of erythromycin and clarithromycin on the pharmacokinetics of intravenously administered digoxin (0.5 mg) in healthy subjects. Nine male subjects participated in three studies (digoxin alone, digoxin with erythromycin, and digoxin with clarithromycin). Subjects took erythromycin (800 mg per day) or clarithromycin (400 mg per day) on the day before digoxin dosing and during the kinetic study. Neither of the macrolides affected serum digoxin concentration-time curves. However, more than 1.3 fold increases in urinary digoxin excretions were observed during erythromycin and clarithromycin coadministration compared with digoxin alone. There were significant differences in renal clearance between macrolide coadministration and the control condition (digoxin alone: 98.4 ml/min; digoxin with erythromycin: 137.3 ml/min; digoxin with clarithromycin: 133.6 ml/min). In conclusion, neither erythromycin nor clarithromycin has a significant effect on serum digoxin disposition after an intravenous administration. Renal digoxin excretion is not inhibited but rather enhanced by both macrolides.
引用
收藏
页码:1159 / 1164
页数:6
相关论文
共 48 条
[1]   QUINIDINE REDUCES BILIARY CLEARANCE OF DIGOXIN IN MAN [J].
ANGELIN, B ;
ARVIDSSON, A ;
DAHLQVIST, R ;
HEDMAN, A ;
SCHENCKGUSTAFSSON, K .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1987, 17 (03) :262-265
[2]   Erythromycin-felodipine interaction: Magnitude, mechanism, and comparison with grapefruit juice [J].
Bailey, DG ;
Bend, JR ;
Arnold, JMO ;
Tran, LT ;
Spence, JD .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 60 (01) :25-33
[3]   Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion [J].
Boyd, RA ;
Stern, RH ;
Stewart, BH ;
Wu, XC ;
Reyner, EL ;
Zegarac, EA ;
Randinitis, EJ ;
Whitfield, L .
JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 40 (01) :91-98
[4]   Transport and epithelial secretion of the cardiac glycoside, digoxin, by human intestinal epithelial (Caco-2) cells [J].
Cavet, ME ;
West, M ;
Simmons, NL .
BRITISH JOURNAL OF PHARMACOLOGY, 1996, 118 (06) :1389-1396
[5]   INFLUENCE OF GASTRIC PH ON DIGOXIN BIOTRANSFORMATION .2. EXTRACTABLE URINARY METABOLITES [J].
GAULT, H ;
KALRA, J ;
AHMED, M ;
KEPKAY, D ;
LONGERICH, L ;
BARROWMAN, J .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1981, 29 (02) :181-190
[6]   Inhibition of triazolam clearance by macrolide antimicrobial agents: In vitro correlates and dynamic consequences [J].
Greenblatt, DJ ;
von Moltke, LL ;
Harmatz, JS ;
Counihan, M ;
Graf, JA ;
Durol, ALB ;
Mertzanis, P ;
Duan, SX .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 64 (03) :278-285
[7]   The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin [J].
Greiner, B ;
Eichelbaum, M ;
Fritz, P ;
Kreichgauer, HP ;
Von Richter, O ;
Zundler, J ;
Kroemer, HK .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (02) :147-153
[8]  
HALKIN H, 1975, CLIN PHARMACOL THER, V17, P385
[9]   DIGOXIN-VERAPAMIL INTERACTION - REDUCTION OF BILIARY BUT NOT RENAL DIGOXIN CLEARANCE IN HUMANS [J].
HEDMAN, A ;
ANGELIN, B ;
ARVIDSSON, A ;
BECK, O ;
DAHLQVIST, R ;
NILSSON, B ;
OLSSON, M ;
SCHENCKGUSTAFSSON, K .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1991, 49 (03) :256-262
[10]   PHARMACOKINETICS OF DIGOXIN AND MAIN METABOLITES DERIVATIVES IN HEALTHY HUMANS [J].
HINDERLING, PH ;
HARTMANN, D .
THERAPEUTIC DRUG MONITORING, 1991, 13 (05) :381-401